HIV Antiretroviral Therapy

Modern HIV treatment is a triumph of medical science, transforming a fatal diagnosis into a manageable chronic condition. As a future clinician, understanding antiretroviral therapy (ART) is essential, not only for managing your patients' health but also for leveraging treatment as a powerful tool to prevent transmission. This guide outlines the current principles for initiating, monitoring, and optimizing ART, focusing on the core concepts that underpin clinical decision-making.

The Foundation: Combination Antiretroviral Therapy

Combination Antiretroviral Therapy (cART), formerly known as Highly Active Antiretroviral Therapy (HAART), is the cornerstone of HIV management. It involves using a minimum of three antiretroviral drugs from at least two different drug classes. This multi-target strategy is non-negotiable because HIV replicates with a high mutation rate. Using a single drug, or monotherapy, allows the virus to rapidly develop drug resistance—mutations that make the medication ineffective. By attacking the virus at multiple stages of its lifecycle simultaneously, cART suppresses viral replication to undetectable levels, preserving immune function and preventing the progression to AIDS.

The standard regimen today is a three-drug combination, typically packaged into a single, once-daily pill to maximize adherence. The goal is to achieve and maintain viral suppression, defined as a viral load below the detection threshold of standard assays (often <20 to <50 copies/mL). A patient with a durably suppressed viral load cannot sexually transmit HIV, a concept known as Undetectable = Untransmittable (U=U), which is a critical public health benefit of effective treatment.

First-Line Treatment: The Role of Integrase Inhibitors

When initiating therapy, selection of the optimal regimen is guided by efficacy, tolerability, and convenience. Currently, integrase strand transfer inhibitor (INSTI)-based regimens are the preferred and recommended first-line options for most people newly diagnosed with HIV. Integrase inhibitors work by blocking the HIV enzyme integrase, which the virus uses to insert its genetic material into the DNA of a host CD4 T-cell. This prevents the cell from being turned into a virus-producing factory.

Regimens like Bictegravir/Emtricitabine/Tenofovir alafenamide or Dolutegravir with a dual-nucleoside reverse transcriptase inhibitor (NRTI) backbone are favored. They offer several advantages: rapid viral load decline, high genetic barrier to resistance (meaning it takes multiple mutations for the virus to become resistant), generally favorable side-effect profiles, and minimal drug-drug interactions. For most patients, treatment should be started as soon as possible after diagnosis, regardless of CD4 count, to improve individual health outcomes and reduce community viral load.

Monitoring Treatment Response: CD4 Count and Viral Load

Once therapy is initiated, monitoring is conducted through two key laboratory tests: CD4 count and HIV viral load. These are not interchangeable; they provide complementary information about the patient's immune status and the treatment's antiviral effectiveness.

The HIV viral load is the most important indicator of therapeutic success. It measures the number of HIV RNA copies per milliliter of blood. You should expect to see the viral load drop significantly within weeks of starting an effective regimen, with the goal of achieving suppression within 3 to 6 months. The viral load is typically measured at initiation, 2-4 weeks after starting, every 3-6 months until suppression, and then every 6 months thereafter. A rising viral load on treatment is a red flag, potentially indicating poor adherence, drug-drug interactions, or the development of drug resistance.

The CD4 count measures the number of helper T-lymphocytes, the primary cells targeted by HIV. It is a marker of immune system health. At diagnosis, a low CD4 count indicates advanced disease and higher risk for opportunistic infections. After starting ART, the CD4 count usually recovers, but more slowly than the viral load drops. While viral load tells you if the treatment is working, the CD4 count tells you how well the patient's immune system is recovering. It is monitored at baseline and typically every 6-12 months once the patient is virologically suppressed.

Guiding Therapy Changes: Drug Resistance Testing

If a patient experiences virologic failure (a confirmed detectable viral load on treatment), drug resistance testing is imperative to guide the selection of a new regimen. This genotypic assay analyzes the genetic sequence of the patient's HIV to identify mutations associated with resistance to specific drugs. There are two main types: standard testing, done while the patient is on a failing regimen, and archived or proviral DNA testing, which can detect resistance mutations even when the virus is suppressed.

The results of this testing are interpreted using established algorithms to determine which drugs are likely to be fully active, partially active, or inactive. The new regimen should ideally include at least two, and preferably three, fully active agents based on this report. Using resistance testing to inform regimen changes helps avoid cycling patients through partially effective therapies, preserves future treatment options, and is a standard of care in managing treatment failure.

Prevention: Pre-Exposure Prophylaxis (PrEP)

Beyond treatment, antiretroviral drugs are used for prevention. Pre-exposure prophylaxis (PrEP) involves prescribing a daily combination pill (typically Emtricitabine/Tenofovir) to HIV-negative individuals at substantial risk of acquiring HIV. When taken consistently, PrEP reduces the risk of acquiring HIV from sex by over 99%. It is a critical tool for key populations, including men who have sex with men, transgender individuals, heterosexuals with high-risk partners, and people who inject drugs.

Effective PrEP programs require regular follow-up—usually every 3 months—for HIV testing (to ensure the individual remains negative), assessment of side effects, screening for other sexually transmitted infections, and reinforcement of adherence counseling. PrEP is a powerful example of a biomedical prevention strategy that, when combined with behavioral interventions, can significantly curb the epidemic.

Common Pitfalls

1. Delaying ART Initiation: A common historical mistake was waiting for a patient's CD4 count to fall below a certain threshold before starting therapy. Current guidelines emphasize "treatment as prevention" and starting immediately upon diagnosis to improve long-term individual outcomes and public health.
2. Inadequate Adherence Counseling: Simply writing a prescription is insufficient. Clinicians must engage in frank, non-judgmental discussions about adherence barriers (e.g., stigma, side effects, routine disruption) and problem-solve with the patient. Poor adherence is the most common pathway to drug resistance.
3. Misinterpreting Lab Values: Confusing the roles of viral load and CD4 count can lead to errors. For instance, a stable CD4 count in a patient with a rising viral load does not indicate treatment success; it is a precursor to immune decline. Conversely, a slow CD4 recovery in a patient with full viral suppression is not a sign of treatment failure.
4. Overlooking PrEP Opportunities: Failing to assess HIV risk and offer PrEP to eligible patients represents a missed prevention opportunity. PrEP is a proactive conversation that should be integrated into primary care and sexual health discussions.

Summary

• Modern HIV treatment relies on combination antiretroviral therapy (cART) to suppress the virus, restore immune function, and prevent transmission.
• Integrase inhibitor-based regimens are the preferred first-line treatment for most patients due to their potency, tolerability, and high barrier to resistance.
• Treatment response is monitored via HIV viral load (the primary marker of efficacy) and CD4 count (a marker of immune recovery).
• Drug resistance testing is a critical tool for selecting an effective new regimen when a patient experiences virologic failure on their current therapy.
• Pre-exposure prophylaxis (PrEP) is a highly effective biomedical strategy for preventing HIV acquisition in at-risk, HIV-negative individuals.